Harper Governments Omnibus Crime Bill C-10 Rejected by USA
Harper Governments Omnibus Crime Bill C-10 Rejected by USA – Conservatives in the United States’ toughest crime-fighting jurisdiction – Texas – say the Harper government’s crime strategy won’t work. “You will spend billions and billions and billions on locking people up,” says Judge John Creuzot of the Dallas County Court. “And there will come a point in time where the public says, ‘Enough!’ And you’ll wind up letting them out.” Adds Representative Jerry Madden, a conservative Republican who heads the Texas House Committee on Corrections, “It’s a very expensive thing to build new prisons and, if you build ’em, I guarantee you they will come. They’ll be filled, OK? Because people will send them there. “But, if you don’t build ’em, they will come up with very creative things to do that keep the community safe and yet still do the incarceration necessary.” These comments are in line with a coalition of experts in Washington, DC, who attacked the Harper government’s omnibus crime package, Bill C-10, in a statement Monday. “Republican governors and state legislators in such states of Texas, South Carolina, and Ohio are repealing mandatory minimum sentences, increasing opportunities for effective community supervision, and funding drug treatment because they know it will improve public safety and reduce taxpayer costs,” said Tracy Velázquez, executive director of the Washington-based Justice Policy Institute. “If passed, C-10 will take Canadian justice policies 180 degrees in the wrong direction, and Canadian citizens will bear the costs …
Technique that removes additional toxins prolongs dialysis patients' lives
Filed under: drug treatment programs washington dc
Washington, DC (February 14, 2013) — A technique that removes additional toxins during dialysis may prolong kidney failure patients' lives, according to a clinical trial appearing in an upcoming issue of the Journal of the American Society Nephrology …
Read more on EurekAlert (press release)
Business Digest
Filed under: drug treatment programs washington dc
Boulder-based cancer drug research company Array BioPharma Inc. (Nasdaq: ARRY) reported decreased revenue and an increased loss for the most recent quarter ended Dec. 31. Array reported that revenue for the quarter was $ 18.4 million, …. The Northeast …
Read more on Boulder County Business Report